Non-Smad TGF-beta signalling

Ludwig Institute for Cancer Research, Biomedical Center, Uppsala University, Box 595, SE 751 24 Uppsala, Sweden.
Journal of Cell Science (Impact Factor: 5.43). 09/2005; 118(Pt 16):3573-84. DOI: 10.1242/jcs.02554
Source: PubMed

ABSTRACT During the past 10 years, it has been firmly established that Smad pathways are central mediators of signals from the receptors for transforming growth factor beta (TGF-beta) superfamily members to the nucleus. However, growing biochemical and developmental evidence supports the notion that alternative, non-Smad pathways also participate in TGF-beta signalling. Non-Smad signalling proteins have three general mechanisms by which they contribute to physiological responses to TGF-beta: (1) non-Smad signalling pathways directly modify (e.g. phosphorylate) the Smads and thus modulate the activity of the central effectors; (2) Smads directly interact and modulate the activity of other signalling proteins (e.g. kinases), thus transmitting signals to other pathways; and (3) the TGF-beta receptors directly interact with or phosphorylate non-Smad proteins, thus initiating parallel signalling that cooperates with the Smad pathway in eliciting physiological responses. Thus, non-Smad signal transducers under the control of TGF-beta provide quantitative regulation of the signalling pathway, and serve as nodes for crosstalk with other major signalling pathways, such as tyrosine kinase, G-protein-coupled or cytokine receptors.

Download full-text


Available from: Carl-Henrik Heldin, Dec 04, 2014
1 Follower
62 Reads
  • Source
    • "Although studies have demonstrated the tumor suppressive role of TGFβ1 during the early stages of hyperplasia and tumor development, it switches to a tumor promoter during the advanced metastatic stages of cancer [14] [26] [34] [52]. TGFβ1, the most ubiquitous and best characterized isoform promotes tumor progression and metastasis in advanced cancers utilizing different pathways; both canonical Smad-dependent pathways and non-canonical Smadindependent pathways [27] [29] [42]. One of the best characterized cellular modifications during EMT in any tissues is the increased expression of mesenchymal cell-surface markers such as N-cadherin and Snail [9] [44] and loss of epithelial markers such as E-cadherin and cytokeratins [9] [19]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Transforming growth factor beta (TGFβ) is believed to play a dual role in prostate cancer. Molecular mechanism by which TGFβ1 suppresses early prostate tumor growth and induces epithelial-to-mesenchymal transition (EMT) in advanced stages is not known. We determined if P21-activated kinase1 (Pak1), which mediates cytoskeletal remodeling is necessary for the TGFβ1 induced prostate cancer EMT. Effects of TGFβ1 on control prostate cancer PC3 and DU145 cells and those with IPA 3 and siRNA mediated Pak1 inhibition were tested for prostate tumor xenograft in vivo and EMT in vitro. TGFβ1 inhibited PC3 tumor xenograft growth via activation of P38-MAPK and caspase-3, 9. Long-term stimulation with TGFβ1 induced PC3 and DU145 cell scattering and increased expression of EMT markers such as Snail and N-cadherin through tumor necrosis factor receptor-associated factor-6 (TRAF6)-mediated activation of Rac1/Pak1 pathway. Selective inhibition of Pak1 using IPA 3 or knockdown using siRNA both significantly inhibited TGFβ1-induced prostate cancer cell EMT and expression of mesenchymal markers. Our study demonstrated that TGFβ1 induces apoptosis and EMT in prostate cancer cells via activation of P38-MAPK and Rac1/Pak1 respectively. Our results reveal the potential therapeutic benefits of targeting TGFβ1-Pak1 pathway for advanced-stage prostate cancer. Copyright © 2015. Published by Elsevier B.V.
    Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 03/2015; 1853(5). DOI:10.1016/j.bbamcr.2015.02.023 · 5.02 Impact Factor
  • Source
    • "Once activated, the TGFß superfamily (including bone morphogenetic proteins (BMPs)) signals via heteromeric complexes of type I (ALK) and type II receptors, recruiting downstream R-Smad proteins (Receptor-regulated Smad: Smad1, Smad2, Smad3, Smad5, and Smad8) and co-Smads (Smad4, serves as a common partner for all R-Smad) before translocating to the nucleus and act as a transcription factor on target genes [21]. TGFß can also exert its biological effects via non-Smad pathways [22]. In noncanonical pathways, TGFßs may transduce their signals via MAP kinases through TGFß-activating kinase (TAK1). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Transforming growth factor beta (TGFb) is a major signalling pathway in joints. This superfamilly is involved in numerous cellular processes in cartilage. Usually, they are considered to favor chondrocyte differentiation and cartilage repair. However, other studies show also deleterious effects of TGFb which may induce hypertrophy. This may be explained at least in part by alteration of TGFb signaling pathways in aging chondrocytes. This review focuses on the functions of TGFb in joints and the regulation of its signaling mediators (receptors, Smads) during aging and osteoarthritis.
    Aging and Disease 12/2014; 5(6):394-405. DOI:10.14336/AD.2014.0500394 · 3.07 Impact Factor
  • Source
    • "In addition to the Smad pathway, also known as the conventional pathway, Smad-independent pathways can be activated by TGFβ, including TGFβ-associated kinase 1 (TAK1) [8], certain MAPKs such as extracellular signal-regulated kinase (ERK) 1 and 2, Jun N-terminal kinase (JNK) and p38 mitogen-activated protein kinase [8], [9]. The PI3K-Akt-mTOR pathway has also been reported to be activated by TGFβ [10]. The importance of these alternative pathways, NF-κB in particular, has been debated. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Transforming growth factor-β (TGFβ) is a key mediator of fibrogenesis. TGFβ is overexpressed and activated in fibrotic diseases, regulates fibroblast differentiation into myofibroblasts and induces extracellular matrix deposition. Platelet-derived growth factor (PDGF) is also a regulator of fibrogenesis. Some studies showed a link between TGFβ and PDGF in certain fibrotic diseases. TGFβ induces PDGF receptor alpha expression in scleroderma fibroblasts. PDGF-C and -D are the most recently discovered ligands and also play a role in fibrosis. In this study, we report the first link between TGFβ and PDGF-D and -C ligands. In normal fibroblasts, TGFβ down-regulated PDGF-D expression and up-regulated PDGF-C expression at the mRNA and protein levels. This phenomenon is not limited to TGFβ since other growth factors implicated in fibrosis, such as FGF, EGF and PDGF-B, also regulated PDGF-D and PDGF-C expression. Among different kinase inhibitors, only TGFβ receptor inhibitors and the IκB kinase (IKK) inhibitor BMS-345541 blocked the effect of TGFβ. However, activation of the classical NF-κB pathway was not involved. Interestingly, in a model of lung fibrosis induced by either bleomycin or silica, PDGF-D was down-regulated, which correlates with the production of TGFβ and other fibrotic growth factors. In conclusion, the down-regulation of PDGF-D by TGFβ and other growth factors may serve as a negative feedback in the network of cytokines that control fibrosis.
    PLoS ONE 10/2014; 9(10):e108656. DOI:10.1371/journal.pone.0108656 · 3.23 Impact Factor
Show more